American Association for Cancer Research

Program

AACR has designated this educational activity for a maximum of 27.75 AMA PRA Category 1 Credit(s)™. Visit the Continuing Medical Education (CME) webpage for details and disclosure information.

SUNDAY, NOVEMBER 7

Educational Sessions 1-2

10:00 a.m.-11:30 a.m.

  • Metabolomics: An Emerging Tool for Defining Complex Biological Systems in Health and Disease

    Chairperson: Steven S. Gross, Weill Cornell Medical College, New York, NY

    Untargeted plasma metabolite profiling: Strategies and approaches for comprehensive characterization of gene mutations and drug actions
    Steven S. Gross

    Metabolomics of disease progression
    Christopher Beecher, University of Michigan, Ann Arbor, MI

    Metabolomics as a unique biochemical approach for therapeutic discovery
    Gary Siuzdak, The Scripps Research Institute, La Jolla, CA

  • Trends in Molecular Epidemiology Research

    Chairperson: Gloria M. Petersen, Mayo Clinic Cancer Center, Rochester, MN

    Introduction
    Gloria M. Petersen

    Gene, environment, and risk factor interaction in pancreatic cancer
    Harvey A. Risch, Yale University, New Haven, CT

    Genomic technologies for variant detection and measurement
    John D. Carpten, Translational Genomics Research Institute, Phoenix, AZ

    Molecular genetic research: Translating discovery into risk assessment and genetic testing
    Gloria M. Petersen

Professional Advancement Session

Chairperson: Margaret R. Spitz, University of Texas MD Anderson Cancer Center, Houston, TX
11:30 a.m.-1:00 p.m.

Opening Remarks
Margaret R. Spitz; and Elizabeth H. Blackburn, University of California, San Francisco, CA

Panel Discussion

* - Adobe Acrobat Reader required

  • Discussants
    Powel H. Brown, University of Texas MD Anderson Cancer Center, Houston, TX
    Andrew J. Dannenberg, Cornell University Weill Medical College, New York, NY
    Judy E. Garber
    Stephen B. Gruber, University of Michigan, Ann Arbor, MI
    Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA
    William G. Nelson
    Electra D. Paskett
    Gloria M. Petersen, Mayo Clinic College of Medicine, Rochester, MN
    Elizabeth A. Platz, Johns Hopkins University School of Public Health, Baltimore, MD
    Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA
    Harvey A. Risch, Yale University, New Haven, CT
    Margaret R. Spitz
    Eva Szabo, National Cancer Institute, Bethesda, MD

 

Lunch on own

11:30 a.m.-1:00 p.m.

Educational Session 3-4

1:00 p.m.-2:30 p.m.

  • Epigenetics

    Chairperson: Ari M. Melnick, Weill Cornell Medical College, New York, NY

    Epigenetic progression in cancer: Implications for prevention
    James G. Herman, Johns Hopkins University, Baltimore, MD

    The clinical and biological impact of aberrant DNA methylation patterning in human cancer 

    Ari M. Melnick

    Therapeutic targeting of oncogenic epigenetic modifiers
    Kapil N. Bhalla, The University of Kansas Cancer Center, Kansas City, KS

  • Team Science and Transdisciplinary Approaches to Cancer Prevention Research Within and Across Institutions

    Chairperson: Sarah Gehlert, Washington University, St. Louis, MO

    Fostering team science and transdisciplinary approaches to cancer prevention: The Centers for Population Health and Health Disparities experience
    Sarah Gehlert

    Team science and transdisciplinarity in cancer prevention research across the life cycle: The Breast Cancer and the Environment Research Program experience
    Robert A. Hiatt, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

    The NCI perspective on the significance and importance of team science and transdisciplinarity for cancer prevention research: The TTURC experience
    Glen Morgan, National Cancer Institute, Bethesda, MD

Educational Sessions 5-6

2:45 p.m.-4:15 p.m.

  • Clinical Trial Novel Design: Retooling Drugs for Prevention

    Chairperson: Andrea U. DeCensi, E.O. Ospedali Galliera, Genova, Italy

    Common drugs associated with reduced cancer risk
    Gad Rennert, CHS National Cancer Control Center, Haifa, Israel

    Efficient trial designs and suitable cohorts to assess preventive agents
    Jack Cuzick, Cancer Research UK, Queen Mary University of London, London, United Kingdom

    Presurgical models to effectively screen preventive agents
    Andrea U. DeCensi

  • The Indigenous Gut Microbiota in Colon Cancer

    Chairperson: Vincent B. Young, University of Michigan, Ann Arbor, MI

    Understanding the structure and function of the gut microbiota
    Vincent B. Young

    Colonic bacteria, inflammation, and colon cancer
    Cynthia L. Sears, Johns Hopkins University, Baltimore, MD

    The microbiota and development of colitis-associated colorectal cancer
    Christian Jobin, University of North Carolina, Chapel Hill, NC

Special Session: View From the NCI

4:30 p.m.-5:15 p.m.

View from the NCI: NCI's Division of Cancer Prevention
Peter Greenwald, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD

View from the NCI: Division of Cancer Control and Population Sciences
Robert T. Croyle, National Cancer Institute, Division of Cancer Control and Population Sciences, Bethesda, MD

Opening Plenary Session

6:00 p.m.-7:30 p.m.

Welcome and Remarks
Margaret Foti, CEO, American Association for Cancer Research, Philadelphia, PA

Eva Szabo, Scientific Program Committee Chairperson, National Cancer Institute, Bethesda, MD

Keynote Address
Telomere biology and cancer
Elizabeth H. Blackburn, University of California, San Francisco, CA

Distinguished Lecture on Targets for Cancer Prevention
Inflammation and cancer: Interweaving microRNA, innate immune, and p53 pathways

Curtis C. Harris, National Cancer Institute, Bethesda, MD

View recent articles from these speakers in AACR journals.

Opening Reception

7:30 p.m.-9:00 p.m.

 

MONDAY, NOVEMBER 8

Plenary Session 1: Personalized Prevention

Chairperson: Scott M. Lippman, University of Texas MD Anderson Cancer Center, Houston, TX
8:00 a.m.-10:00 a.m.

Proximity of personalized risk and predictive markers to the clinic
Scott M. Lippman

Nicotine-dependence pharmacogenetics: Implications for personalized therapy
Robert A. Schnoll, University of Pennsylvania, Philadelphia, PA

ODC genotype as prognostic and predictive factors in colorectal carcinogenesis and prevention
Eugene W. Gerner, University of Arizona, Tucson, AZ

Selenium, genes, and cancer prevention
Jing Ma, Brigham and Women’s Hospital, Boston, MA

View recent articles from these speakers in AACR journals.

Concurrent Sessions 1-3

10:15 a.m.-12:00 p.m.

  • Infections

    Chairperson: Douglas R. Lowy, National Cancer Institute, Bethesda, MD

    Current and future HPV vaccines
    Douglas R. Lowy

    Immunotherapy of established lesions caused by high-risk HPV
    Cornelis J.M. Melief, University Hospital Leiden, Leiden, The Netherlands

    HBV vaccination to prevent hepatocellular carcinoma
    Mei-Hwei Chang, National Taiwan University Hospital, Taipei, Taiwan

  • Recently Completed Developmental Trials in Chemoprevention

    Chairperson: Howard H. Bailey, University of Wisconsin Comprehensive Cancer Center, Madison, WI

    Pertinent chemoprevention drug development issues in today's session
    Howard H. Bailey

    Phase 0 chemoprevention trial of SR13668, a novel AKT inhibitor, in normal volunteers
    Joel M. Reid, Mayo Clinic College of Medicine, Rochester, MI

    Phase II study of genistein in men with prostate cancer
    Raymond C. Bergan, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

    Phase IIB randomized clinical chemoprevention trial of a soybean-derived compound (Bowman-Birk inhibitor concentrate) for oral leukoplakia
    Frank L. Meyskens, University of California Irvine Chao Family Comprehensive Cancer Center, Orange, CA

    Phase IIB study to evaluate the safety and efficacy of topical difluoromethylornithine and topical diclofenac in the treatment of sun-damaged skin
    Joanne M. Jeter, Arizona Cancer Center, Tucson, AZ

    Discussion
    Moderator: Howard H. Bailey

    In Memoriam: Karen Aubrey Johnson (1946-2010)
    A tribute to Dr. Karen Johnson will take place from 12:00-12:20.

  • Interventions to Reduce Cancer Health Disparities

    Chairperson: Electra D. Paskett, Ohio State University Comprehensive Cancer Center, Columbus, OH

    Community-based intervention to reduce liver cancer disparities in Asian Americans: A cluster randomized trial
    Roshan Bastani, UCLA School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, CA

    Randomized trial of a lay health advisor and computer intervention to increase mammography screening in African American women
    Electra D. Paskett

    Improving follow-up to abnormal breast cancer screening in an urban population: A patient navigation intervention
    Tracy A. Battaglia, Boston University School of Medicine, Boston, MA

    Inequalities in colorectal cancer screening uptake: Results from the first 2.6 million invitations in the organized screening program in the UK*
    Jane Wardle, University College London, London, United Kingdom

Lunch on own

12:00 p.m.-1:15 p.m.

Concurrent Sessions 4-6

1:15 p.m.-3:00 p.m.

  • Molecular Targets for Cancer Prevention

    Chairperson: Eva Szabo, National Cancer Institute, Bethesda, MD

    PPARgamma in aerodigestive cancer prevention
    Eva Szabo

    Strategies to target the insulin/IGF-I receptor family for cancer prevention
    Michael N. Pollak, McGill University, Montreal, QC, Canada

    PI3K as a target for lung cancer chemoprevention
    Andrea H. Bild, University of Utah, Salt Lake City, UT

    STAT2 contributes to promotion of colorectal and skin carcinogenesis*
    Ana M. Gamero, Temple University, Philadelphia, PA

  • Prostate Cancer

    Chairperson: Raymond C. Bergan, Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

    Early molecular changes in prostate carcinogenesis
    William G. Nelson, Johns Hopkins University, Baltimore, MD

    The role of estrogen in prostate cancer development and prevention
    Shuk-Mei Ho, University of Cincinnati, Cincinnati, OH

    Decision making in prostate cancer screening
    Kathryn L. Taylor, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

    Randomized presurgical trial of finasteride vs. flutamide vs. placebo in prostate cancer*
    Silvia Zanardi, E.O. Ospedali Galliera, Genoa, Italy, and European Institute of Oncology, Milan, Italy

  • Individualized Diet and Cancer Prevention

    Chairperson: Johanna Wyss Lampe, Fred Hutchinson Cancer Research Center, Seattle, WA

    Soy foods and cancer risk: How does the relation vary in individuals with different ethnicity, diet, and lifestyle?
    Gertraud Maskarinec, Cancer Research Center of Hawaii, Honolulu, HI

    Green tea and pomegranate: The role of metabolites in chemoprevention
    Susanne M. Henning, David Geffen School of Medicine, University of California, Los Angeles, CA

    Vegetable constituents and biotransformation enzymes: The effect of genetic variation on response
    Johanna Wyss Lampe

    Interactions between plasma levels of 25-hydroxyvitamin D and insulin-like growth factor (IGF)-1, IGF-binding proteins, and C-peptide with risk of colorectal cancer*
    Kana Wu, Harvard School of Public Health, Boston, MA

Plenary Session 2: New Approaches to Identifying High-Risk Populations

Chairperson: Avrum E. Spira, Boston University, Boston, MA
3:15 p.m.-5:15 p.m.

Identifying the smoker at risk for lung cancer
Avrum E. Spira

Cancer risk-stratification through biophotonic detection of field carcinogenesis
Hemant K. Roy, University of Chicago Pritzker School of Medicine, Evanston, IL

Somatic evolution and neoplastic progression in Barrett’s esophagus: Lessons in space and time
Brian J. Reid, Fred Hutchinson Cancer Research Center, Seattle, WA

New insights into genetic susceptibility to breast cancer
Douglas Easton, University of Cambridge, Cambridge, United Kingdom

View recent articles from these speakers in AACR journals.

Ninth Annual AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research Lecture

5:15 p.m.-6:15 p.m.

Validating biomarkers to probe the etiology and prevention of hepatocellular carcinoma
John D. Groopman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Behavioral Science in Cancer Research Networking Event

6:00 p.m.-7:30 p.m.

Please visit the Networking Sessions and Social Events webpage for details.

Poster Session A

6:15 p.m.-8:45 p.m.

 

TUESDAY, NOVEMBER 9

Report on AACR-NCI Think Tank: Charting the Future of Cancer Prevention

Chairperson: Raymond N. DuBois, University of Texas MD Anderson Cancer Center, Houston, TX
7:00 a.m.-8:00 a.m.

Plenary Session 3: Bioenergetics and Cancer

Co-Chairpersons: John A. Milner, National Cancer Institute, Rockville, MD, and Sharon Ross, National Cancer Institute, Rockville, MD
8:00 a.m.-10:00 a.m.

Introduction
John A. Milner

Exercise, adiposity, and cancer
Anne McTiernan, Fred Hutchinson Cancer Research Center, Seattle, WA

Nrf2 and cancer protection
Rafael de Cabo, NIH-NIA Laboratory of Experimental Gerontology, Baltimore, MD

Cancer cure and prevention: Lessons learned from a small but highly effective agent
Peter L. Pedersen, Johns Hopkins University, Baltimore, MD

Obesity and mTORC1 signaling pathway
George Thomas, University of Cincinnati, Cincinnati, OH

View recent articles from these speakers in AACR journals.

Concurrent Sessions 7-9

10:15 a.m.-12:00 p.m.

  • Lung Cancer Prevention

    Chairperson: Jenny T. Mao, University of New Mexico, Albuquerque, NM

    Polycyclic aromatic hydrocarbon tetraols: Potentional phenotypic indicators of lung cancer susceptibility in smokers
    Stephen S. Hecht, Masonic Cancer Center, University of Minnesota, Minneapolis, MN

    Natural history of bronchial preneoplasia
    Stephen Lam, British Columbia Cancer Agency, Vancouver, BC, Canada

    Neutrophil elastase as a chemopreventive target for lung cancer
    McGarry Houghton, University of Pittsburgh, Pittsburgh, PA

    Efficient designs for lung cancer prevention trials: Lessons learned and moving forward
    J. Jack Lee, University of Texas MD Anderson Cancer Center, Houston, TX

  • Karen A. Johnson Memorial Session:
    Novel Targets and Strategies for Breast Cancer Prevention

    Chairperson: Powel H. Brown, University of Texas MD Anderson Cancer Center, Houston, TX

    Implications of the cancer stem cell hypothesis for breast cancer prevention
    Max S. Wicha, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI

    Breast cancer prevention: Predictors and outcomes of patient decision making
    Suzanne C. O'Neill, Lombardi Comprehensive Cancer Center at Georgetown University, Washington, DC

    PARP inhibitors: Early promise in breast and ovarian cancer prevention
    Judy E. Garber, Dana-Farber Cancer Institute, Boston, MA

    Effects of presurgical administration of tea polyphenols in women with operable breast cancer*
    Julie L. Campbell, Columbia University Medical Center, New York, NY

    Please note that the tribute to Dr. Karen Johnson has been moved to Monday, November 8 from 12:00 p.m. to 12:20 p.m. in Room 201B.

  • Molecular Approaches to Early Detection

    Chairperson: Samir M. Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA

    Autoantibodies and early detection of lung cancer
    Samir M. Hanash

    The EGFR conundrum: EGFR-based diagnostics in the era of precision medicine
    Nita J. Maihle, Yale University School of Medicine, New Haven, CT

    Molecular approaches to early detection of pancreatic cancer
    Michael A. Hollingsworth, University of Nebraska Medical Center Eppley Cancer Center, Omaha, NE

    Identification of age-dependent biomarkers for early detection of breast cancer using metabolite profiling: A multisite study*
    Vincent M. Asiago, Purdue University, West Lafayette, IN

Lunch on own

12:00 p.m.-1:15 p.m.

Concurrent Sessions 10-12

1:15 p.m.-3:00 p.m.

  • The Microenvironment

    Chairperson: Thea D. Tlsty, University of California, San Francisco, CA

    Stromal-epithelial interactions in early carcinogenesis
    Thea D. Tlsty

    Stromal signals from the involuting microenvironment that are important in postpartum breast cancer
    Pepper Jo Schedin, University of Colorado Denver, Aurora, CO

    Profiling of tumors to identify factors that contribute to cancer health disparities
    Stephan Ambs, National Cancer Institute, Bethesda, MD

    A new resource to accelerate research into the cause and prevention of breast cancer: The Love/Avon Army of Women*
    Leah Wilcox, Dr. Susan Love Research Foundation, Santa Monica, CA

  • Advances in the Genetics, Screening and Prevention of Cancers in Cancer Susceptibility Syndromes

    Chairperson: Katherine L. Nathanson, University of Pennsylvania, Philadelphia, PA

    Genetics of pheochromocytoma and paraganglioma defines medical management
    Katherine L. Nathanson

    Whole-body MRI and PET for screening in patients with neurofibromatosis
    Scott R. Plotkin, Massachusetts General Hospital, Boston, MA

    Cancer prevention in Lynch syndrome
    Sir John Burn, Institute of Human Genetics, International Center for Life, Newcastle-upon-Tyne, United Kingdom

    The willingness to accept chemoprevention strategies by women at increased risk of breast cancer*
    Mfon Cyrus-David, University of Texas Health Science Center, Houston, TX

  • Inflammation and Cancer Prevention

    Chairperson: Andrew J. Dannenberg, Weill Cornell Medical College, New York, NY

    The prostaglandin-aromatase connection: Implications for breast carcinogenesis
    Andrew J. Dannenberg

    The inflammation-EMT-cancer initiating cell axis in the pathogenesis of lung cancer: Breaking ground in the pursuit of targeted chemoprevention
    Steven M. Dubinett, University of California, David Geffen School of Medicine, Los Angeles, CA

    The role of inflammation and stromal cells in gastrointestinal cancers
    Timothy C. Wang, Columbia University, New York, NY

    Low-fat diet reduces NF-κB regulated inflammatory cytokines and angiogenic factors in plasma of men with prostate cancer*
    Wendy Demark-Wahnefried, University of Alabama, Birmingham, AL

Plenary Session 4: Understanding Neoplastic Progression: Questions and Controversies

Chairperson: Carlo C. Maley, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
3:15 p.m.-5:15 p.m.

Evolutionary concepts of cancer
Carlo C. Maley

Cancer stem cells?
Simon Tavaré, University of Cambridge, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

Altered gene expression patterns in phenotypically normal cells from individuals heterozygous for mutations in tumor suppressor genes: Identification of candidate biomarkers of cancer risk
Alfonso Bellacosa, Fox Chase Cancer Center, Philadelphia, PA

Why do benign growths so often progress to malignant cancers?
John W. Pepper, University of Arizona, Tucson, AZ

View recent articles from these speakers in AACR journals.

Poster Session B

5:15 p.m.-7:45 p.m.

Molecular Epidemiology Working Group (MEG) Town Meeting and Reception

7:30 p.m.-9:00 p.m.

Please visit the Networking Sessions and Social Events webpage for details.

 

WEDNESDAY, NOVEMBER 10

Plenary Session 5: Bringing Prevention and Early Detection to the Public: A Global Perspective

Chairperson: Michael J. Thun, American Cancer Society, Atlanta, GA
8:00 a.m.-10:00 a.m.

Global trends in cancer: The imperative for prevention
Michael J. Thun

Policy and environmental approaches to cancer prevention: The New York City experience
Thomas A. Farley, New York City Department of Health and Mental Hygiene, New York, NY

From basic science to public health: The Canadian approach to oral leukoplakia

Miriam P. Rosin, British Columbia Cancer Research Center, Vancouver, BC, Canada

The Australian skin cancer prevention experience: Lessons learned and global challenges ahead
Craig Sinclair, Cancer Council Victoria, Carlton, VIC, Australia

View recent articles from these speakers in AACR journals.

Concurrent Sessions 13-15

10:15 a.m.-12:00 p.m.

  • Molecularly Based Approaches to Colorectal Cancer Prevention

    Chairperson: Paul J. Limburg, Mayo Clinic College of Medicine, Rochester, MN

    Immunotherapy for prevention of colorectal cancer
    Robert E. Schoen, University of Pittsburgh, Pittsburgh, PA

    Next-generation stool DNA testing
    David A. Ahlquist, Mayo Clinic College of Medicine, Rochester, MN

    HDAC inhibitors in colorectal cancer chemoprevention
    Roderick H. Dashwood, Linus Pauling Institute, Oregon State University, Corvallis, OR

    A novel approach for colorectal cancer chemoprevention by targeting APC-deficient cells for apoptosis
    Xiangwei Wu, University of Texas MD Anderson Cancer Center, Houston, TX

    Panel Discussion

 

  • Head and Neck Cancer Prevention

    Chairperson: Mary E. Reid, Roswell Park Cancer Institute, Buffalo, NY

    Motivating individual behavior change through theory-driven community engagement
    Henrietta L. Logan, University of Florida, Gainesville, FL

    Implications of fluorescent screening for detection of premalignancy and cancer
    Mary E. Reid

    Identifying the premalignant lesion at high risk for progression to cancer
    Li Mao, University of Maryland Dental School, Baltimore, MD

    Randomized placebo controlled trial of pioglitazone for oral premalignant lesions: A cross consortium collaborative study in progress*
    Jay O. Boyle, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Communicating Cancer Risks: High-Risk Populations, the Public, and Physician Communication

    Chairperson: Mary B. Daly, Fox Chase Cancer Center, Philadelphia, PA

    Communicating cancer risk to high-risk patients and their families
    Mary B. Daly

    The importance of form, content, and context in the design and effectiveness of risk communication methods
    James G. Dolan, University of Rochester, Rochester, NY

    Making data talk: Communicating science to lay audiences
    Bradford W. Hesse, National Cancer Institute, Bethesda, MD

    HPV vaccine adherence in urban youth*
    J. Kathleen Tracy, University of Maryland School of Medicine, Baltimore, MD

Departure

* - Short talk from selected proffered abstracts